GlassScriptPhysician profile
Sonalee K Shroff
NPI 1073571964
$4,364.17
in general payments reported to CMS, 2019-2025
47 companies · $949 in 2025
The $949 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $301 · 2021: $44.87 · 2022: $520 · 2023: $992 · 2024: $1,033 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $438.15 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $378.46 | 2019-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $256.54 | 2024-2025 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $251.43 | 2019-2025 | Opdivo |
| Seagen INC. | $248.98 | 2020-2023 | Adcetris |
| Gilead Sciences, INC. | $202.02 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $193.27 | 2019-2024 | |
| Abbvie INC. | $179.51 | 2024-2025 | |
| Daiichi Sankyo INC. | $155.15 | 2020-2025 | Enhertu, Vanflyta |
| Genentech USA, INC. | $150.17 | 2019-2024 | Alecensa, Tecentriq, Tecentriq Hybreza |
| Janssen Biotech, INC. | $141.73 | 2019-2025 | Talvey, Rybrevant |
| Amgen INC. | $139.74 | 2019-2022 | |
| Pfizer INC. | $130.28 | 2019-2025 | |
| Lilly USA, LLC | $118.63 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $92.52 | 2023-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonalee Shroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.